1. Home
  2. MEIP vs HCTI Comparison

MEIP vs HCTI Comparison

Compare MEIP & HCTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • HCTI
  • Stock Information
  • Founded
  • MEIP 2000
  • HCTI 2020
  • Country
  • MEIP United States
  • HCTI United States
  • Employees
  • MEIP N/A
  • HCTI N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • HCTI Retail: Computer Software & Peripheral Equipment
  • Sector
  • MEIP Health Care
  • HCTI Technology
  • Exchange
  • MEIP Nasdaq
  • HCTI Nasdaq
  • Market Cap
  • MEIP 13.3M
  • HCTI 13.5M
  • IPO Year
  • MEIP 2003
  • HCTI 2021
  • Fundamental
  • Price
  • MEIP $6.60
  • HCTI $0.05
  • Analyst Decision
  • MEIP Hold
  • HCTI
  • Analyst Count
  • MEIP 1
  • HCTI 0
  • Target Price
  • MEIP N/A
  • HCTI N/A
  • AVG Volume (30 Days)
  • MEIP 2.8M
  • HCTI 364.5M
  • Earning Date
  • MEIP 09-18-2025
  • HCTI 08-18-2025
  • Dividend Yield
  • MEIP N/A
  • HCTI N/A
  • EPS Growth
  • MEIP N/A
  • HCTI N/A
  • EPS
  • MEIP N/A
  • HCTI N/A
  • Revenue
  • MEIP N/A
  • HCTI $11,291,000.00
  • Revenue This Year
  • MEIP N/A
  • HCTI N/A
  • Revenue Next Year
  • MEIP N/A
  • HCTI N/A
  • P/E Ratio
  • MEIP N/A
  • HCTI N/A
  • Revenue Growth
  • MEIP 33.76
  • HCTI N/A
  • 52 Week Low
  • MEIP $1.46
  • HCTI $0.01
  • 52 Week High
  • MEIP $9.00
  • HCTI $1.90
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 81.52
  • HCTI 68.41
  • Support Level
  • MEIP $5.75
  • HCTI $0.01
  • Resistance Level
  • MEIP $9.00
  • HCTI $0.03
  • Average True Range (ATR)
  • MEIP 0.85
  • HCTI 0.00
  • MACD
  • MEIP 0.39
  • HCTI 0.00
  • Stochastic Oscillator
  • MEIP 62.50
  • HCTI 87.61

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About HCTI Healthcare Triangle Inc.

Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their effort to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Platform Services.

Share on Social Networks: